1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Spotlyte - ROI?

Discussion in 'Allergan' started by anonymous, Feb 25, 2019 at 6:55 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I know it’s the golden egg...but I hear the ivory Manhattan towers may be crumbling under a total inability to pull through any ROI to sales?

    Anyone have any thoughts?
     

  2. anonymous

    anonymous Guest

    i don’t believe there is any ROI. It is just buzz around beauty industry targeting rich new yorkers. On the other hand, I am certain that BCG had their ROI and got paid tons of money to make a few people look good in their “moonwalker” jobs.
     
  3. anonymous

    anonymous Guest

    moonwalker/spotlyte is a money drain. The idea isn’t bad, but the execution is poor. Almost a year in and they have 14K followers - my neighbor has more followers and she sells pillows in the area. They have used expensive bcg consultants and hired too many people for what? To feel good about and promote themselves, hiring their friends, having cushy jobs and delivering NO RESULTS.
     
  4. anonymous

    anonymous Guest

    Easy answer, zero! The concept is a joke and the execution is even worse. Customers couldn’t care less about it.